Particularly of interest as an alternative cancer antigen for MM CAR-T cell therapy is CD2 subset 1 (CS1, CD319 or signaling lymphocytic activation molecule family member 7 [SLAMF7]). This evidence concerns the gene SLAMF7 and cancer.